Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment

Robert A. HarringtonProfessor and Chair of Medicine, Stanford University

“The urgency of COVID-19 must not diminish the scientific rigor with which we approach COVID-19 treatment. While these medications may work against COVID-19 individually or in combination, we recommend caution with these medications for patients with existing cardiovascular disease.”

“Hydroxychloroquine and azithromycin have increased cardiovascular toxicity, should not be administered outside of a clinical trial, and require close additional cardiovascular monitoring and treatment.”

Andrea M. RussoDirector of Electrophysiology, Cooper University Hospital

“Given the potential for increased risks related to combinations of medications that prolong the QT interval, we urge careful consideration to ensure patients with cardiovascular disease or others at increased risk can be monitored appropriately.”